Sign In
Buy BTGOF
$2.73
+0.130 (+5.00%)
At Close: Jun 03, 2026
BT looks towards end of fibre roll-out millstone
07:42am, Friday, 01'st Nov 2024
BT Group PLC (LSE:BT.A)results updates have been dull affairs of late with revenues and earnings static and most of the emphasis on how many customers it has lost. But things might be changing, especi
BT Openreach competitor Community Fibre secures £125mln in funding
09:24am, Thursday, 24'th Oct 2024
Community Fibre has secured an additional £125 million in funding from a group of lenders including JP Morgan, Barclays, LBBW, Sequoia Investment Management Company and Alpha Bank. The BT Openreach f
BT Group may benefit from regulatory clarity, says US bank with sector re-rating expected to continue
04:46pm, Wednesday, 23'rd Oct 2024
BT Group PLC (LSE:BT.A) was one of the stocks highlighted in research by a leading investment bank, which assessed the potential for future significant gains across the sector, which, up until this y
BT, Virgin broadband ads were ‘likely to mislead' customers
03:31am, Wednesday, 09'th Oct 2024
Virgin Media, BT Group PLC (LSE:BT.A), BT subsidiaries EE and Plusnet, and TalkTalk have been told by the Advertising Standards Agency to make mid-contract price rises in their broadband offerings cle
BT rival Cityfibre says ‘widespread consolidation' of altnets inevitable
06:14am, Wednesday, 02'nd Oct 2024
The UK's high-speed broadband sector is heading down a one-way path to a “widespread consolidation” of its smaller players, prominent BT Openreach rival CityFibre has predicted. “Given the finan
BT rival Hyperoptic pens annual wins and losses
07:12am, Tuesday, 01'st Oct 2024
Full-fibre alternative network provider Hyperoptic has delivered an annual statement infused with signs of optimism coupled with some clear stress points. Hyperoptic typically targets urban areas acro
BT bags £105m from copper wire recycling
04:47am, Monday, 30'th Sep 2024
BT Group PLC (LSE:BT.A) has received £105 million for recycling old copper wires retrieved from its fast-fibre upgrade programme. Network subsidiary Openreach said: “As we look to recover and reuse
Vodafone ordered to remove ads following BT complaint
03:43am, Wednesday, 18'th Sep 2024
Vodafone Group PLC (LSE:VOD) has been ordered to pull several advertisements after the Advertising Standards Authority (ASA) ruled that claims made in three ads about its broadband services were misle
BT Group: Peak CapEx At Openreach
11:52am, Monday, 16'th Sep 2024
BT Group has reached peak CapEx, reducing expenditure outlook and boosting free cash flow potential, making it a more attractive investment. The fiber rollout is progressing, with 11-16 million homes
LUND, SWEDEN / ACCESSWIRE / September 14, 2024 / BioInvent International (STO:BINV) Preliminary data presented at ESMO 2024 demonstrate BT-001 induces tumor regression in patients who failed previous
Preliminary data presented at ESMO 2024 demonstrate that BT-001 induces tumor regression in patients who failed previous anti-PD(L)-1 treatment
BT spots 2,000 potential attacks on its network a second
06:10am, Thursday, 12'th Sep 2024
Britain's BT said it was spotting 2,000 signals of potential cyber-attacks across its network every second, as criminals were increasingly using disposable "bots" to try to evade existing blocking and
Planning laws preventing faster internet, claims BT boss
10:27am, Tuesday, 10'th Sep 2024
Planning regulation is slowing down the rollout of faster internet, the chief executive of BT's consumer division has told Sky News.
BioInvent and Transgene to Present Promising Initial Phase 1/2a Data on Oncolytic Virus, BT-001, at ESMO 2024
01:20am, Monday, 09'th Sep 2024
LUND, SE / ACCESSWIRE / September 09, 2024 / BioInvent International (STO:BINV) BT-001 monotherapy showed stable disease and injected lesions shrinkage in advanced solid tumor patients. Promising effi
Transgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncolytic Virus, BT-001, at ESMO 2024
01:00am, Monday, 09'th Sep 2024
BT-001 monotherapy showed stable disease and shrinkage of injected lesions in patients with advanced solid tumors. BT-001 in combination with KEYTRUDA® (pembrolizumab) showed promising efficacy data
